A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company.[1] Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires.[2] Reference to the innovator product is an integral component of the approval.[3]
Unlike with generic drugs of the more common small-molecule type, biologics generally exhibit high molecular complexity and may be quite sensitive to changes in manufacturing processes. Despite that heterogeneity, all biopharmaceuticals, including biosimilars, must maintain consistent quality and clinical performance throughout their lifecycle.[4]
Drug-related authorities such as the European Medicines Agency (EMA) of the European Union, the United States Food and Drug Administration (FDA), and the Health Products and Food Branch of Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies demonstrate that the biological product is highly similar to the reference product, despite minor differences in clinically inactive components, animal studies (including the assessment of toxicity), and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics). They are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and is intended to be used and for which licensure is sought for the biological product.[citation needed]
The World Health Organization (WHO) published its "Guidelines for the evaluation of similar biotherapeutic products (SBPs)" in 2009. The purpose of this guideline is to provide an international norm for evaluating biosimilars.[5][6][7][8]
The EMA has granted marketing authorizations for more than 50 biosimilars since 2006. The first biosimilar of a monoclonal antibody to be approved worldwide was a biosimilar of infliximab in the EU in 2013.[9] On March 6, 2015, the FDA approved the United States' first biosimilar product, the biosimilar of filgrastim called filgrastim-sndz (trade name Zarxio) by Sandoz.
Approval processes
United States
In the United States, the Food and Drug Administration (FDA) held that new legislation was required to enable them to approve biosimilars to those biologics originally approved through the PHS Act pathway.[10] Additional Congressional hearings have been held.[11] On March 17, 2009, the Pathway for Biosimilars Act was introduced in the House.[2] Since 2004 the FDA has held a series of public meetings on biosimilars.[12][13]
The FDA gained the authority to approve biosimilars (including interchangeables that are substitutable with their reference product) as part of the Patient Protection and Affordable Care Act signed into law by President Obama on March 23, 2010.[citation needed]
The FDA has previously approved biologic products using comparability, for example, Omnitrope in May 2006, but this like Enoxaparin was also to a reference product, Genotropin, originally approved as a biologic under the FD&C Act.[14]
On March 6, 2015, Zarxio obtained the first approval of FDA.[15] Sandoz's Zarxio is biosimilar to Amgen's Neupogen (filgrastim), which was originally licensed in 1991. This is the first product to be passed under the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), which was passed as part of the Affordable Healthcare Act. But Zarxio was approved as a biosimilar, not as an interchangeable product, the FDA notes. And under the BPCI Act, only a biologic that has been approved as an "interchangeable" may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. The FDA said its approval of Zarxio is based on review of evidence that included structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamics data, clinical immunogenicity data and other clinical safety and effectiveness data that demonstrates Zarxio is biosimilar to Neupogen.[citation needed]
In March 2020, most protein products that were approved as drug products (including every insulin currently on the market as of December 2019[update]) are scheduled to open up to biosimilar and interchangeable competition in the United States.[16] However, "chemically synthesized polypeptides" are excluded from this transition, which means that a product that falls within this category won't be able to come to market as a biosimilar or interchangeable product, but will have to come to the market under a different pathway.[16]
Background
Cloning of human genetic material and development of in vitro biological production systems has allowed the production of virtually any recombinant DNA based biological substance for eventual development of a drug. Monoclonal antibody technology combined with recombinant DNA technology has paved the way for tailor-made and targeted medicines. Gene- and cell-based therapies are emerging as new approaches.
Recombinant therapeutic proteins are of a complex nature (composed of a long chain of amino acids, modified amino acids, derivatized by sugar moieties, folded by complex mechanisms). These proteins are made in living cells (bacteria, yeast, animal or human cell lines). The ultimate characteristics of a drug containing a recombinant therapeutic protein are to a large part determined by the process through which they are produced: choice of the cell type, development of the genetically modified cell for production, production process, purification process, formulation of the therapeutic protein into a drug.
After the expiry of the patent of approved recombinant drugs (e.g., insulin, human growth hormone, interferons, erythropoietin, monoclonal antibodies and more) any other biotech company can develop and market these biologics (thus called biosimilars).
The typical reference product has undergone numerous changes in its manufacturing processes, and such changes in the manufacturing process (ranging from a change in the supplier of cell culture media to new purification methods or new manufacturing sites) was substantiated with appropriate data and was approved by the EMA.
The current concept of development of biosimilar monoclonal antibodies follows the principle that an extensive state of the art physicochemical, analytical and functional comparison of the molecules is complemented by comparative non-clinical and clinical data that establish equivalent efficacy and safety in a clinical "model" indication that is most sensitive to detect any minor differences (if these exist) between the biosimilar and its reference monoclonal antibody also at the clinical level.
The EMA has recognized this fact, which has resulted in the establishment of the term "biosimilar" in recognition that, whilst biosimilar products are similar to the original product, they are not exactly the same.[17]
Originally the complexity of biological molecules led to requests for substantial efficacy and safety data for a biosimilar approval. This has been progressively replaced with a greater dependence on assays, from quality through to clinical, that show assay sensitivity sufficient to detect any significant difference in dose.[18] However, the safe application of biologics depends on an informed and appropriate use by healthcare professionals and patients. Introduction of biosimilars also requires a specifically designed pharmacovigilance plan. It is difficult and costly to recreate biologics because the complex proteins are derived from living organisms that are genetically modified. In contrast, small molecule drugs made up of a chemically based compound can be easily replicated and are considerably less expensive to reproduce. In order to be released to the public, biosimilars must be shown to be as close to identical to the parent innovator biologic product based on data compiled through clinical, animal, analytical studies and conformational status.[19][20]
Generally, once a drug is released in the market by the FDA, it has to be re-evaluated for its safety and efficacy once every six months for the first and second years. Afterward, re-evaluations are conducted yearly, and the result of the assessment should be reported to authorities such as FDA. Biosimilars are required to undergo pharmacovigilance (PVG) regulations as its reference product. Thus biosimilars approved by the EMA are required to submit a risk management plan (RMP) along with the marketing application and have to provide regular safety update reports after the product is in the market. The RMP includes the safety profile of the drug and proposes the prospective pharmacovigilance studies.
Several PK studies, such as studies conducted by Committee for Medicinal Products for Human Use (CHMP), have been conducted under various ranges of conditions; Antibodies from an originator's product versus antibodies from a biosimilar; combination therapy and monotherapy; various diseases, etc. on the purpose to verify comparability in pharmacokinetics of the biosimilar with the reference medicinal product in a sufficiently sensitive and homogeneous population.
Nomenclature
In the European Union, no unique identifier of a biosimilar medicine product is required, as the same rules are followed as for all biologics.[citation needed]
The US decided on a different approach, requiring the assignment of a four-letter suffix to the nonproprietary name of the original product to distinguish between innovator drugs and their biosimilars.[21] Japan has similar requirements.[22] The suffix approach has been criticized on the grounds of compromising the INN system and delaying the marketing of biosimilars.[22] Australia decided not to use a 4-letter suffix.[23][24][25]
A version of the four-letter suffix has been proposed to the WHO as the biological qualifier (BQ). It is not part of the international nonproprietary name (INN), but is proposed to be managed under the same registry.[26] The report 1 of the May 2017 WHO Expert Consultation on Improving Access to and Use of Similar Biotherapeutic Products, published in October 2017, revealed on page 4, that following the outcome arising from the meeting: "No consensus was reached on whether WHO should continue with the BQ... WHO will not be proceeding with this at present."[27]
Australia
Biosimilars available in Australia include adalimumab, bevacizumab, enoxaparin, epoetin lambda, etanercept, filgrastim, follitropin alfa, infliximab, insulin aspart, insulin glargine, pegfilgrastim, rituximab, teriparatide, and trastuzumab.[28]
Egypt
A research article about "Maximizing the benefits of using biosimilars in Egypt" proposed a regulatory framework for biosimilars in Egypt. The article summarized the recommendations of a number of stakeholders.[29]
Key Findings and Recommendations of the article
Pricing: The experts suggested a mandatory discount of 30–40% on the price of the first biosimilar compared to its originator, with subsequent biosimilars receiving additional discounts. It was also recommended that biosimilar prices be revised periodically, either annually or biennially.
Reimbursement: A significant emphasis was placed on using Health Technology Assessment (HTA), specifically cost-effectiveness analysis (CEA) and budget impact analysis (BIA), when manufacturers seek to extend reimbursement indications beyond those of the originator. Additionally, experts proposed that the first biosimilar, offering a minimum 50% discount compared to the originator, be granted immunity from removal from the formulary for a specified period.
Uptake: The study highlighted the need for policies that enhance both prescriber and patient acceptance of biosimilars. Strategies include disseminating educational materials, implementing financial incentives for prescribing biosimilars as first-line therapy, and using co-payments to encourage the choice of less expensive biosimilars over more costly biologics.
Post-Marketing and Pharmacovigilance: The importance of establishing registries and conducting real-world evidence studies to monitor biosimilar efficacy and safety was also emphasized. A pharmacovigilance framework specific to biosimilars and biologics was suggested to be more effective than the existing general framework.
European Union
Biosimilar medicines approved in the European Union (EU) are interchangeable with their reference medicine or with an equivalent biosimilar.[30]
As of October 2024, the US FDA has approved 60 biosimilars.[132][133]
BPCI Act
The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) was originally sponsored and introduced on June 26, 2007, by Senator Edward Kennedy (D-MA). It was formally passed under the Patient Protection and Affordable Care Act (PPAC Act), signed into law by President Barack Obama on March 23, 2010. The BPCI Act was an amendment to the Public Health Service Act (PHS Act) to create an abbreviated approval pathway for biological products that are demonstrated to be highly similar (biosimilar) to a Food and Drug Administration (FDA) approved biological product.[134] The BPCI Act is similar, conceptually, to the Drug Price Competition and Patent Term Restoration Act of 1984 (also referred to as the "Hatch-Waxman Act") which created biological drug approval through the Federal Food, Drug, and Cosmetic Act (FFD&C Act). The BPCI Act aligns with the FDA's longstanding policy of permitting appropriate reliance on what is already known about a drug, thereby saving time and resources and avoiding unnecessary duplication of human or animal testing. The FDA has released a total of four draft guidelines related to biosimilar or follow-on biologics development. Upon the release of the first three guidance documents the FDA held a public hearing on May 11, 2012.[135]
In 2018, the FDA released a Biosimilars Action Plan to implement regulations from the BPCI, including limiting the abuse of the Risk Evaluation and Mitigation Strategy (REMS) system for evergreening and transitioning insulin and human growth hormone to regulation as biologics rather than drugs.[136]
^"Biosimilar medicines regulation". Therapeutic Goods Administration (TGA). April 4, 2018. Archived from the original on December 30, 2021. Retrieved December 29, 2021.
^"Biosimilars". U.S. Food and Drug Administration. July 27, 2021. Archived from the original on August 28, 2021. Retrieved August 28, 2021. This article incorporates text from this source, which is in the public domain.
Este artículo trata sobre la ocurrencia del ruido en la música. Para el ruido como una forma de música, véase Noise music. Jimi Hendrix revolucionó el rock y jazz al incorporar ruido a través de técnicas como el feedback, distorsión, wah, fuzz, disonancia y volumen estridente. Un módulo Dolby 361 tipo A para la reducción de ruido. En la música, el ruido es descrito como un sonido sin tono, indeterminado, descontrolado, estridente, no musical e indeseado. El ruido es un componente i...
Lokomotif uap seri C3318 dan C3065 di Museum Transportasi Taman Mini Indonesia Indah (TMII). Lokomotif uap adalah jenis lokomotif yang menggunakan tenaga mesin uap untuk menarik rangkaian kereta. Lokomotif uap menggunakan bahan bakar batu bara, kayu, atau minyak untuk menghasilkan uap dalam pendidih. Uap ini kemudian menggerakkan piston yang secara mekanis terhubung dengan roda penggeraknya. Baik bahan bakar dan air dipasok dalam lokomotif, baik ditampung pada lokomotif atau menggunakan tende...
Floral exhibition in Columbus, Ohio in 1992 AmeriFlora '92 logo AmeriFlora '92 was an international horticultural exhibition held in Columbus, Ohio, United States from April 20 to October 12, 1992. Taking place on 88 acres (356,123 m2) of landscaped grounds at Franklin Park, the exhibition cost $95 million to produce and attracted 5.5 million visitors. The exhibition was billed as the first international flower show in the United States.[1] Origins AmeriFlora centerpiece. The sculptur...
← Waw Zayn Het → Fenisia Ibrani Aram Suryani Arab ז ܙ ز Alfabetturunan Yunani Latin Kiril Ζ Z З Representasi fonemik: z Urutan dalam alfabet: 7 Nilai huruf/Gematria: 7 Zayin (juga dieja Zain atau Zayn atau sekadar Zay) adalah huruf ketujuh dalam banyak aksara Semit, termasuk abjad Fenisia
У Вікіпедії є статті про інші географічні об’єкти з назвою Камерон. Місто Камеронангл. Cameron Координати 35°19′34″ пн. ш. 79°15′11″ зх. д. / 35.32611111113877200° пн. ш. 79.2530555555837850° зх. д. / 35.32611111113877200; -79.2530555555837850Координати: 35°19′34″ пн. ш. 79°15′11″ зх.&...
Najránنجران Región Coordenadas 17°29′30″N 44°07′56″E / 17.491666666667, 44.132222222222Capital NajránEntidad Región • País Arabia SauditaSubdivisiones 8 distritosSuperficie • Total 149 511 km²Población (2010) • Total 505 652 hab. • Densidad 4,25 hab/km² Sitio web oficial [editar datos en Wikidata] Najrán (en árabe: نجران) es una de las regiones de Arabia Saudita, situada...
American auto racing series This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: NASCAR Advance Auto Parts Weekly Series – news · newspapers · books · scholar · JSTOR (March 2017) (Learn how and when to remove this template message) NASCAR Advance Auto Parts Weekly SeriesCategoryStock car racingCountryUnited Stat...
В Википедии есть статьи о других людях с такой фамилией, см. Джонсон. Джауан Джонсонангл. JaJuan Johnson Гравлин-Дюнкерк Позиция Тяжёлый форвард / Центровой Рост 208 см Вес 100 кг Гражданство США Дата рождения 8 февраля 1989(1989-02-08) (34 года) Место рождения Индианаполис, Индиана, СШ�...
Bahasa Kutai Tenggarong Tenggarong Dituturkan diIndonesiaWilayah Kalimantan Timur Kutai Kartanegara Kutai Timur Samarinda Bontang Kelurahan Guntung Penutur320.000 (1981)Rumpun bahasaAustronesia Melayu-PolinesiaIndonesia BaratBorneo Utara RayaMelayikBahasa Kutai Tenggarong Kode bahasaISO 639-1-ISO 639-2-ISO 639-3vkt Portal BahasaSunting kotak info • L • B • PWBantuan penggunaan templat ini Bahasa Kutai Tenggarong adalah sebuah dialek bahasa Kutai dalam rum...
Geographical features of Malawi Malawi's cities, towns and larger villages Location of Malawi Malawi is a landlocked country in southeast Africa. It is wholly within the tropics; from about 9°30S at its northernmost point to about 17°S at the southernmost tip. The country occupies a thin strip of land between Zambia and Mozambique, extending southwards into Mozambique along the valley of the Shire River. In the north and north east it also shares a border with Tanzania. Malawi is connected ...
American TV personality and game show hostess (born 1957) Vanna WhiteWhite next to the puzzle board during a taping of Wheel of Fortune on February 8, 2006BornVanna Marie Rosich[1] (1957-02-18) February 18, 1957 (age 66)North Myrtle Beach, South Carolina, U.S.Occupation(s)Game-show co-host,[2] television personality, model, actress, authorYears active1977–presentKnown forWheel of FortuneSpouse George Santo Pietro (m. 1990; d...
Untuk yang lain, lihat Tradisi (disambiguasi). Perayaan liburan sebagai salah satu warisan tradisi. Tradisi atau leluri (bahasa Latin: traditio, diteruskan) adalah sebuah bentuk perbuatan yang dilakukan berulang-ulang dengan cara yang sama.[1] Kebiasaan yang diulang-ulang ini dilakukan secara terus menerus karena dinilai bermanfaat bagi sekelompok orang, sehingga sekelompok orang tersebut melestarikannya. Kata Tradisi diambil dari bahasa latin ''Tradere'' yang bermakna mentr...
Bupati PesawaranLambang Kabupaten PesawaranPetahanaDendi Ramadhonasejak 26 Februari 2021KediamanPendapa Kabupaten PesawaranMasa jabatan5 tahunDibentuk2007Pejabat pertamaHaris FadilahSitus webpesawarankab.go.id Berikut ini adalah Daftar Bupati Pesawaran dari masa ke masa. No Bupati Mulai Jabatan Akhir Jabatan Prd. Ket. Wakil Bupati 1 Drs. H.Haris FadilahM.M. 2 November 2007 2008 1 [Ket. 1] 2 Djunaidi DjayaS.H., M.H. 2008 2009 2 [Ket. 2] 3 Drs. H.Haris FadilahM.M. 2009 2010...
Компоненты хромосомы:(1) Хроматида(2) Центромера(3) Короткое плечо(4) Длинное плечо Хромати́да (от др.-греч. χρῶμα — «цвет», «краска» и εἶδος — «вид») — структурный элемент хромосомы, формирующийся в интерфазе в ядре клетки в результате удвоения хромосомы. Содержан�...
Estate of the Holy Roman Empire (1140–1806); county of Austria (1806–1919) For other uses, see Tyrol. (Princely) County of Tyrol(Gefürstete) Grafschaft Tirol (German)Contea (principesca) del Tirolo (Italian)Contea (da prinz) dl Tirol (Ladin)1140–1919 Flag Coat of arms Map of the County of Tyrol (1799)StatusState of the Holy Roman Empire (until 1806),Crown land of the Habsburg monarchy, of the Austrian Empire (from 1804) and of Cisleithanian Austria-Hungary (from 1867)Cap...
Italian jurist and politician (1935–2022) Egidio AlagnaAlagna in 1983Member of the Chamber of Deputies of ItalyIn office12 July 1983 – 22 April 1992ConstituencyPalermo-Trapani-Agrigento-Caltanissetta constituency [it] Personal detailsBorn31 October 1935Marsala, ItalyDied3 May 2022(2022-05-03) (aged 86)Palermo, ItalyPolitical partyPSIOccupationJudge Egidio Alagna (31 October 1935 – 3 May 2022) was an Italian politician. A member of the Italian Socialist Party, ...
1971 film directed by A. C. Tirulokchandar BabuPosterDirected byA. C. TirulokchandarScreenplay byA. C. TirulokchandarBased onOdayil Ninnuby P. KesavadevStarringSivaji GanesanVijayasriSowcar JanakiVennira Aadai NirmalaCinematographyM. Viswanatha RaiEdited byR. G. GopuMusic byM. S. ViswanathanProductioncompanyCine Bharath ProductionsDistributed byAVM ProductionsRelease date 18 October 1971 (1971-10-18) Running time169 minutesCountryIndiaLanguageTamil Babu is a 1971 Indian Tamil l...
